Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Lymphoid 1

Conditions

Mucositis 1Lymphoma 1Hodgkin Disease 1

Interventions

angiotensin I (1-7) 3Leuprolide 2Hydrocortisone 2Bariatric Surgery 2methylnaltrexone 1lorcaserin 1apraglutide 1Vitamin E 1Vaccinium myrtillus extract 1Therapeutics 1Surveys and Questionnaires 1Standard of Care 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Quality of Life 1Practice Guidelines as Topic 1Ovidrel 1Nicotine 1Monitoring, Physiologic 1Midazolam 1Losartan 1Lansoprazole 1Holistic Health 1High-Energy Shock Waves 1Furosemide 1Fibroblast Growth Factor 7 1Exercise 1Diet, Vegetarian 1Diet, Vegan 1Diet Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × apraglutide × Other × Clear all
NCT03417765 2024-10-24

Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas

VectivBio AG

Phase 1/2 Withdrawn
LymphoidOther

Hodgkin Disease, Lymphoma, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡